ZA941926B - Heterocyclic compounds their preparation and use - Google Patents
Heterocyclic compounds their preparation and useInfo
- Publication number
- ZA941926B ZA941926B ZA941926A ZA941926A ZA941926B ZA 941926 B ZA941926 B ZA 941926B ZA 941926 A ZA941926 A ZA 941926A ZA 941926 A ZA941926 A ZA 941926A ZA 941926 B ZA941926 B ZA 941926B
- Authority
- ZA
- South Africa
- Prior art keywords
- preparation
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK93310A DK31093D0 (fr) | 1993-03-19 | 1993-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA941926B true ZA941926B (en) | 1995-09-18 |
Family
ID=8092112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA941926A ZA941926B (en) | 1993-03-19 | 1994-03-18 | Heterocyclic compounds their preparation and use |
Country Status (16)
Country | Link |
---|---|
US (1) | US5559106A (fr) |
EP (1) | EP0691969A1 (fr) |
JP (1) | JPH08507536A (fr) |
KR (1) | KR100313051B1 (fr) |
CN (1) | CN1041930C (fr) |
AU (1) | AU685783B2 (fr) |
CA (1) | CA2158545A1 (fr) |
DK (1) | DK31093D0 (fr) |
FI (1) | FI954386A0 (fr) |
HU (1) | HUT73419A (fr) |
IL (1) | IL108800A (fr) |
NO (1) | NO305286B1 (fr) |
NZ (1) | NZ262365A (fr) |
TW (1) | TW304195B (fr) |
WO (1) | WO1994021639A1 (fr) |
ZA (1) | ZA941926B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4314592A1 (de) * | 1993-04-28 | 1994-11-03 | Schering Ag | Benzo(f)chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
ATE190616T1 (de) * | 1994-09-16 | 2000-04-15 | Novo Nordisk As | (1,2,4)triazolo(4,3-a)chinoxylinonderivate, ihre darstellung und verwendung als antagonisten von ampa-rezeptoren |
JPH10506620A (ja) * | 1994-09-16 | 1998-06-30 | ノボ ノルディスク アクティーゼルスカブ | 〔1,2,4〕トリアゾロ〔4,3−a〕キノキサリノン誘導体、それらの調製方法及び使用 |
US5679680A (en) * | 1995-02-16 | 1997-10-21 | Warner-Lambert Company | α-substituted hydrazides having calpain inhibitory activity |
FR2743363A1 (fr) * | 1996-01-10 | 1997-07-11 | Rhone Poulenc Rorer Sa | 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-a-ones substituees en position 2, leur preparation et les medicaments les contenant |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
WO1999024434A1 (fr) | 1997-11-11 | 1999-05-20 | Ono Pharmaceutical Co., Ltd. | Composes de pyrazine condenses |
AU2298399A (en) * | 1998-02-06 | 1999-08-23 | Yoshitomi Pharmaceutical Industries, Ltd. | Novel azapeptide type hydroxamic acid derivatives |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
WO2008072779A1 (fr) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Dérivé de quinoxaline |
AU2010219598A1 (en) | 2009-03-05 | 2011-09-22 | Astellas Pharma Inc. | Quinoxaline compounds |
EP2338492A1 (fr) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Procédés et compositions pour le traitement de la maladie d'Alzheimer |
CA2810659A1 (fr) | 2010-09-07 | 2012-03-15 | Astellas Pharma Inc. | Compose quinoxaline |
EP2723744B1 (fr) * | 2011-06-27 | 2016-03-23 | Janssen Pharmaceutica, N.V. | Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]-quinoxaline |
ES2855575T3 (es) | 2012-06-26 | 2021-09-23 | Janssen Pharmaceutica Nv | Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4354027A (en) * | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
US4547501A (en) * | 1983-09-02 | 1985-10-15 | Pfizer Inc. | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents |
US5153196A (en) * | 1991-06-05 | 1992-10-06 | Eli Lilly And Company | Excitatory amino acid receptor antagonists and methods for the use thereof |
AU3767793A (en) * | 1992-04-03 | 1993-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Fused quinoxalinone derivative and pharmaceutical composition containing the same |
-
1993
- 1993-03-19 DK DK93310A patent/DK31093D0/da not_active Application Discontinuation
-
1994
- 1994-02-25 CA CA002158545A patent/CA2158545A1/fr not_active Abandoned
- 1994-02-25 NZ NZ262365A patent/NZ262365A/en unknown
- 1994-02-25 HU HU9502726A patent/HUT73419A/hu unknown
- 1994-02-25 JP JP6520538A patent/JPH08507536A/ja active Pending
- 1994-02-25 AU AU62018/94A patent/AU685783B2/en not_active Ceased
- 1994-02-25 CN CN94191979A patent/CN1041930C/zh not_active Expired - Fee Related
- 1994-02-25 KR KR1019950703970A patent/KR100313051B1/ko not_active IP Right Cessation
- 1994-02-25 EP EP94908979A patent/EP0691969A1/fr not_active Withdrawn
- 1994-02-25 WO PCT/DK1994/000077 patent/WO1994021639A1/fr not_active Application Discontinuation
- 1994-02-28 TW TW083101703A patent/TW304195B/zh active
- 1994-03-01 IL IL108800A patent/IL108800A/en active IP Right Grant
- 1994-03-18 ZA ZA941926A patent/ZA941926B/xx unknown
- 1994-12-07 US US08/350,744 patent/US5559106A/en not_active Expired - Fee Related
-
1995
- 1995-09-18 NO NO953673A patent/NO305286B1/no not_active IP Right Cessation
- 1995-09-18 FI FI954386A patent/FI954386A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
IL108800A (en) | 1998-02-22 |
KR100313051B1 (ko) | 2002-02-28 |
HU9502726D0 (en) | 1995-11-28 |
IL108800A0 (en) | 1994-06-24 |
AU685783B2 (en) | 1998-01-29 |
EP0691969A1 (fr) | 1996-01-17 |
US5559106A (en) | 1996-09-24 |
CN1041930C (zh) | 1999-02-03 |
DK31093D0 (fr) | 1993-03-19 |
TW304195B (fr) | 1997-05-01 |
NO953673D0 (no) | 1995-09-18 |
WO1994021639A1 (fr) | 1994-09-29 |
CN1122601A (zh) | 1996-05-15 |
NO305286B1 (no) | 1999-05-03 |
HUT73419A (en) | 1996-07-29 |
JPH08507536A (ja) | 1996-08-13 |
FI954386A (fi) | 1995-09-18 |
FI954386A0 (fi) | 1995-09-18 |
NZ262365A (en) | 1997-05-26 |
NO953673L (no) | 1995-11-17 |
KR960701057A (ko) | 1996-02-24 |
CA2158545A1 (fr) | 1994-09-29 |
AU6201894A (en) | 1994-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL115717A0 (en) | Heterocyclic compounds and their preparation and use | |
GB9422158D0 (en) | N-acylindoles and related compounds | |
NZ247205A (en) | Intermediate compounds: 4-ethyl-5-fluoropyrimidine and 4-chloro-6-ethyl-5-fluoropyrimidine | |
HU9600932D0 (en) | In-alkyl-n-arylpyrimidinamines and derivatives thereof | |
EP0788489A4 (fr) | Composes heterocycliques et leur utilisation | |
ZA947833B (en) | 4-Arylamino-benzopyran and related compounds | |
ZA941993B (en) | Amidine derivatives containing heterocyclic groups the preparation and use thereof | |
ZA941926B (en) | Heterocyclic compounds their preparation and use | |
ZA927172B (en) | Heterocyclic compounds and their preparation and use. | |
ZA929770B (en) | Heterocyclic compounds and their preparation and use | |
EG19877A (en) | Cyanophenylpyroles compounds and their use as herbicides | |
EP0482649A3 (en) | Cm-chitin derivatives and use thereof | |
ZA952410B (en) | Substituted heterocyclic carboxamioesters their preparation and their use as pharmaceuticals | |
ZA942882B (en) | 2-Amino-4-quinolyl-dihydropyridines processes for their preparation and their use | |
GB9411045D0 (en) | Compounds and use | |
IL114490A0 (en) | Heterocyclic compounds their preparation and their use | |
AU1292995A (en) | Bis-oxazolidine compounds and their use | |
ZA942246B (en) | Novel imidazolo-quinoxalinones their preparation and use | |
GB9501907D0 (en) | Allatostatins and their use | |
HU9500177D0 (en) | 3-aryluracil derivatives and their use as herbicides | |
GB9306456D0 (en) | Composition and use | |
GB9324725D0 (en) | Ficyclic compounds and preparation thereof | |
ZA958962B (en) | Heterocyclic compounds and their preparations and use | |
GB9408859D0 (en) | Composition and use | |
GB9308091D0 (en) | Compounds and use |